A pilot study in patients with established advanced liver fibrosis using pirfenidone
- 1 November 2006
- Vol. 55 (11), 1663-1665
- https://doi.org/10.1136/gut.2006.107136
Abstract
PFD is an orally bioavailable pyridone derivative (5-methyl-1-phenyl-2-(1H)-pyridone) that affects a variety of profibrogenic cytokines and its mechanism of action mostly resides in its anti-inflammatory and antifibrotic activity.4– , 6 Here we present data obtained from a pilot clinical trial evaluating the safety and efficacy of PFD in 15 patients with established advanced liver disease caused by hepatitis C virus chronic infection. This is the first report showing improvements in liver histology (that is, necrosis, inflammation, steatosis, fibrosis, and cell regeneration) 12 months after PFD therapy. Colour Doppler ultrasound guided liver biopsies were obtained at baseline and after 12 months of PFD treatment and evaluated for stage of fibrosis and grade of activity according to the modified …Keywords
This publication has 5 references indexed in Scilit:
- Fibrosis in chronic liver diseases: diagnosis and managementJournal of Hepatology, 2005
- The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen α1(I), TIMP-1 and MMP-2Digestive and Liver Disease, 2004
- Pirfenidone effectively reverses experimental liver fibrosisJournal of Hepatology, 2002
- Mechanisms and therapy of hepatic fibrosis: Report of the AASLD single topic basic research conferenceJournal of Hepatology, 2000
- Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapyJournal of Hepatology, 1999